EVGN Evogene Ltd. IFRS Annual reports only
Agricultural Chemicals · Nasdaq · SEC CIK 1574565 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $930,000 |
| Cost of revenue | $4.09M | $2.38M | $1.49M | $909,000 | $767,000 |
| Gross profit | -$241,000 | $3.20M | $1.49M | $766,000 | $163,000 |
| R&D expense | $7.99M | $12.51M | $16.20M | $20.79M | $21.12M |
| SG&A expense | $4.29M | $6.99M | $5.38M | $6.48M | $7.25M |
| Operating income | -$14.03M | -$18.80M | -$22.23M | -$26.94M | -$30.95M |
| Interest expense | $1.93M | $3.36M | $928,000 | $3.33M | $1.41M |
| Pretax income | -$13.50M | -$14.81M | -$21.95M | -$29.75M | -$30.43M |
| Income tax | $1,000 | $9,000 | $19,000 | $90,000 | $13,000 |
| Net income | -$8.48M | -$16.48M | -$23.88M | -$26.64M | -$27.79M |
| EBITDA | -$12.89M | -$17.42M | -$20.93M | -$25.43M | -$29.65M |
| EPS (basic) | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 |
| EPS (diluted) | 1.08 | -2.90 | -5.20 | -6.44 | -0.69 |
| Weighted avg. shares (diluted) | 7.87M | 5.70M | 4.59M | 4.14M | 40.43M |
| Balance sheet | |||||
| Cash & equivalents | $12.96M | $15.30M | $20.77M | $28.98M | $32.33M |
| Short-term investments | — | $10,000 | $10.29M | $0 | $3.00M |
| Receivables | $317,000 | $1.09M | $357,000 | $348,000 | $281,000 |
| Inventory | $210,000 | $1.82M | $76,000 | $566,000 | $92,000 |
| Current assets | $15.63M | $21.59M | $34.47M | $37.75M | $56.89M |
| PP&E, netmay include right-of-use assets (IFRS) | $812,000 | $1.80M | $2.46M | $2.50M | $2.07M |
| Intangibles | $0 | $12.20M | $13.17M | $14.14M | $15.21M |
| Total assets | $20.05M | $39.86M | $51.10M | $56.13M | $76.30M |
| Current liabilities | $3.44M | $18.70M | $6.94M | $5.62M | $6.88M |
| Total liabilities | $8.07M | $25.03M | $22.42M | $21.34M | $12.88M |
| Shareholders' equity | -$82,000 | -$1.45M | $12.05M | $27.93M | $53.65M |
| Shares outstanding | 8.72M | 6.51M | 5.08M | 41.26M | 41.17M |
| Cash flow statement | |||||
| Operating cash flow | -$13.50M | -$19.70M | -$21.58M | -$23.68M | -$24.72M |
| Capital expenditure | $135,000 | $626,000 | $577,000 | $1.17M | $847,000 |
| Free cash flow | -$13.64M | -$20.33M | -$22.15M | -$24.85M | -$25.56M |
| Investing cash flow | $17.74M | $9.62M | -$4.54M | $13.27M | -$20.57M |
| Financing cash flow | -$6.60M | $4.66M | $18.15M | $9.34M | $30.28M |
| Depreciation & amortization | $1.14M | $1.38M | $1.30M | $1.51M | $1.30M |
| Stock-based compensation | $654,000 | $1.24M | $1.11M | $1.19M | $2.61M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.